Pharma and Biotech
Period Ending | Period | Revenue (£m) | Pre-tax (£m) | EPS | Dividend |
---|---|---|---|---|---|
31-Mar-24 | Interim | 80.22 | (7.86) | (1.21)p | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-19 | 124.01 | (58.48) | (10.72)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-20 | 105.57 | (22.57) | (3.80)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-21 | 125.06 | (9.18) | (1.93)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-22 | 157.71 | (21.38) | (4.34)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-23 | 169.48 | (12.69) | (2.41)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-24 | 169.65 | 7.95 | (1.00)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-25 | 189.55 | 16.35 | 1.00p | 44.0 | n/a | n/a | n/a | 0.0% |
30-Sep-26 | 213.20 | 24.15 | 1.70p | 25.9 | 0.4 | +70% | n/a | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
5 Yr High | 5 Yr Low | 5 Yr Avg | Curr / Avg | |
---|---|---|---|---|
Latest | n/a | n/a | n/a | 0 |
Find out about IFRS and how this affects the financial infomation for all UK companies.
Currency | UK Pounds |
Share Price | 44.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 48.00 |
52 Week Low | 34.00 |
Volume | 43,784 |
Shares Issued | 739.78m |
Market Cap | £325.50m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
16:35 | 4 @ 44.00p |
16:35 | 1 @ 44.00p |
16:35 | 1 @ 44.00p |
16:35 | 2 @ 44.00p |
16:21 | 4,515 @ 42.72p |
Chair | Peter George |
CFO | Septima Maguire |
CEO | Trond Williksen |
You are here: research